In re Dexilant Antitrust Litigation

Background

The case concerns a settlement agreement between the manufacturer of Dexilant, a protein pump inhibitor, and a generic-drug manufacturer. Defendants TWi Pharmaceuticals, Inc. and TWi Pharmaceuticals USA, Inc. moved for sanctions against the plaintiffs under Federal Rule of Civil Procedure 11(b), 28 U.S.C. § 1927, and the court’s inherent authority. Defendant Takeda Pharmaceuticals U.S.A., Inc. did not join the motion.

TWi argued that the plaintiffs could not support their allegation that TWi could have launched its generic product by June 15, 2020. TWi also argued that the plaintiffs had failed to conduct a reasonable inquiry and had continued the case despite possessing information that allegedly disproved their claims.

Rule 11 sanctions

Rule 11 requires that factual claims in court filings have evidentiary support, or are likely to have support after a reasonable opportunity for investigation or discovery, and that legal arguments be supported by existing law or a nonfrivolous argument for changing the law. The court noted that Rule 11 sanctions are an extraordinary remedy and that a sanctions motion is not a proper way to test the legal sufficiency of pleadings or litigate disputed factual issues.

The court had previously found that the plaintiffs plausibly alleged that TWi would have obtained approval for its generic product by June 2020 in a hypothetical world without the 2015 settlement. Discovery was still ongoing, and the parties disputed whether the settlement caused TWi not to seek prompt approval. Because the plaintiffs’ allegations had survived the motion to dismiss and TWi had not shown that the factual or legal contentions violated Rule 11, the court denied TWi’s motion for Rule 11 sanctions.

The court also rejected TWi’s attempt to use the sanctions motion to revisit the earlier ruling on the motion to dismiss. It explained that TWi’s arguments about the evidentiary record and the ultimate merits of the antitrust claims were more appropriately raised on a motion for summary judgment.

Section 1927 sanctions

Section 1927 permits sanctions against an attorney who unreasonably and vexatiously multiplies court proceedings. The court stated that this requires subjective bad faith, such as knowingly or recklessly making a frivolous argument or pursuing a meritorious claim to harass an opponent.

The court held that TWi’s disagreement with the substance of the plaintiffs’ allegations did not establish the required recklessness or knowing bad faith. The court therefore denied TWi’s motion for sanctions under Section 1927.

Inherent-authority sanctions

A court’s inherent authority permits sanctions for conduct such as willfully disobeying a court order or acting in bad faith, vexatiously, or for oppressive reasons. The court emphasized that this power must be used cautiously and that the moving party bears the burden of showing bad faith or an improper purpose.

The court concluded that TWi had not come close to meeting that burden and denied the request for sanctions under the court’s inherent authority.

Disposition

The court denied TWi’s motion for sanctions in its entirety under all three asserted bases: Rule 11, 28 U.S.C. § 1927, and the court’s inherent authority. The order did not decide the ultimate merits of the antitrust claims. The court set a further case-management conference for October 14, 2026, and stated that the order disposed of Docket No. 193.